NCT07475390

99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging

Molecular Imaging of Brain Tumor Using 99mTc-1-thio-D-glucose SPECT/CT and 18F-Fluoroethyl-l-tyrosine PET/CT in Primary and Recurrent Glioma Patients

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

An open-label, single-center study with 99mTc-1-thio-D-glucose single photon emission computed tomography / computed tomography (SPECT/CT) and 18F-fluoroethyl-l-tyrosine (18F-FET) positron emission tomography / computed tomography (PET/CT) in primary and recurrent glioma patients, where the primary endpoint of the study is to compare imaging properties of 99mTc-1-thio-D-glucose SPECT/CT and 18F-FET PET/CT of brain tumor Imaging.

Detailed description

The primary objectives are: \- To compare 99mTc-1-thio-D-glucose SPECT/CT and 18F-FET PET/CT properties in primary and recurrent glioma patients The secondary objectives are: \- To compare the accumulation levels of 99mTc-1-thio-D-glucose and 18F-FET depending on the pathomorphological (biopsy/surgical material) and molecular genetic (Ki-67, isocitrate dehydrogenase 1/2 (IDH1/2) mutations, p53 expression) characteristics of the tumor.

Conditions

• Glioma (Any Grade) in the Brain

Interventions

Type	Name	Description
DRUG	99mTc-1-thio-D-glucose	One single injection of 99mTc-1-thio-D-glucose, followed by SPECT/CT imaging 1 hour after injection.
DRUG	18F-FET	One single injection of 18F-FET, followed by gamma camera imaging PET/CT 20 minutes after injection.

Timeline

• Start date: 2026-02-15
• Primary completion: 2027-12-31
• Completion: 2028-05-31
• First posted: 2026-03-16
• Last updated: 2026-03-17

Locations

1 site across 1 country: Russia